Tetrahydropyrrolobenzodiazepines

ABSTRACT

4,5,6,7 - TETRAHYDROPYRROLO(3,2,1 -JK)(1,4)BENZODIAZEPINES, 4,5,6,7 - TETRAHYDROPYRROLO(1,2,3 - EF)(1,5)BENZODIAZEPINES, 4,5 - DIHYDROPYRROLO(3,2,1 - JK)(1,4)BENZODIAZEPIN - 7(6H) - ONES, 4,5-DIHYDROPYRROLO(1,2,3 -EF)(1,5) BENZODIAZEPIN-6(7H)-ONES AND PROCESSES FOR PREPARING THE SAME. SAID COMPOUNDS EXHIBIT TRANQUILIZING AND ANTICONVULSANT ACTIVITY.

United States Patent 61 litre 3,642,821 Patented Feb. 15, 1972 3,642,821 TETRAHYDROPYRROLOBENZODIAZEPINES Jackson B. Hester, Jr., Portage, Mich., assignor to The Upjohn Company, Kalamazoo, Mich.

No Drawing. Filed Nov. 3, 1969, Ser. No. 873,693 Int. Cl. C07d 53/02 US. Cl. 260-3263 16 Claims ABSTRACT OF THE DISCLOSURE 4,5,6,7 tetrahydropyrrolo[3,2,1 jk][l,4]benzodiazepines, 4,5,6,7 tetrahydropyrrolo[1,2,3 ef] [1,5]benzodiazepines, 4,5 dihydropyrrolo[3,2,l jk] [1,4]benzodiazepin 7 (6H) ones, 4,5-dihydropyrrolo[1,2,3 ef] [1,5] benzodiazepin-6(7H)-ones and processes for preparing the same. Said compounds exhibit tranquilizing and anticonvulsant activity.

BRIEF SUMMARY OF THE INVENTION This invention relates to novel 4,5,6,7-tetrahydropyrrolo[3,2,1 jk][1,4]benzodiazepines (I), 4,5,6,7-tetrahydropyrro1o[l,2,3 ef][1,5]benzodiazepines (II), 4,5-dihydropyrrolo[3,2,1 jk] [l,4]benzodiazepin 7(6H)-ones (III), 4,5dihydropyrrolo[1,2,3 ef][1,5]benzodiazepin 6(7H)-ones (IV) and processes for preparing the same.

The novel compounds of this invention have the formulae wherein R is selected from the group consisting of hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive, alkoxy of from 1 to 3 carbon atoms, inclusive, and halogen; wherein R is selected from the group consisting of hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive, 4- oxo-4-(p-fluorophenyl)butyl, and the group wherein n is an integer of from 2 to 4, inclusive, and R is alkyl of from 1 to 3 carbon atoms, inclusive; and wherein R" is hydrogen or the group wherein R is the same as above.

The term novel compounds of this invention, as used throughout the specification embraces the compounds represented by Formulae I, H, III and IV above, and the acid addition salts of (a) the compounds represented by Formulae I and II and (b) the compounds represented by Formulae III and IV wherein R is as defined above.

The term halogen is inclusive of chlorine, bromine and fluorine.

The compounds of Formula I, except those compounds of Formula I wherein R is 4-oxo-4-(p-fluorophenyl) butyl can be prepared by reducing the corresponding compounds of Formula III and the compounds of Formula II can be prepared by reducing the compounds of Formula IV. The reduction processes are illustrated by the following equations.

wherein R and R are the same as above, and R is selected from the group consisting of hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive, and

wherein R'" and n are the same as above.

Compounds of Formula I wherein R is 4-oxo-4-(pfluorophenyl)butyl can be prepared by a process illustrated by Equation 0.

wherein R and R" are the same as above.

Compounds of Formulae III :and IV wherein R" is hydrogen can be prepared by the processes illustrated by Equations D and B, respectively.

R t 2] R N N HN HN IVa can be prepared by the processes illustrated by Equations F and G, respectively.

/RIII Hello Limit CHZN\ R R R!!! O= N I I.

III

I I 0 o IVa. IVb

wherein R, R and R are the same as above.

DETAILED DESCRIPTION Processes A and B are conducted by reacting the 4,5- dihydropyrrolo 3,2,1 jk] 1,4] benzodiazepin-7 6H -ones (111a) and the 4,5-dihydropyrrolo[1,2,3-ef][l,5]benzodiazepin-6(7H)-ones (IV), respectively, with either lithium aluminum hydride or diborane in the presence of an aprotic solvent such as ether, dioxane, tetrahydrofuran or diglyme at a temperature of 0 to 100 C. and a reaction time of 1 to 18 hours. The product is recovered from the reaction mixture by conventional procedures, such as crystallization, evaporation, chromatography and combinations thereof.

This method is not utilized to prepare compounds of Formula I wherein R is 4-oxo-4-(p-fluorophenyl)butyl because the carbonyl in the side chain as well as the carbonyl of the lactam moiety could be reduced thereby.

In process C, compounds of Formula I wherein R is 4-oxo-4-(p-fiuorophenyl)butyl are prepared by refluxing compounds having the formula of Ib with 4-chloro-4- fluorobutyrophenone in an inert solvent for 18 to 48 hours. Solvents that may be utilized include benzene, toluene, xylene, 4-methyl-2-pentanone and the like. Preferably, the reaction is conducted in the presence of a catalyst such as potassium iodide and an acid acceptor such as sodium carbonate. The product is recovered by conventional procedures such :as crystallization, evaporation, chromatography or a combination thereof.

In process D, the 4,5-dihydropyrrolo[3,2,1-jk] [1,4] benzodiazepin 8(6H)-oues (IIIb) are prepared by dehydrogenating the corresponding 1,2,4,5-tetrahydropyrrolo[3,2,l-jk][1,4]benzodiazepin 7 (6H ones (V). This dehydrogenation may be performed by either of two procedures.

In the first procedures the dehydrogenation is conducted by reacting the appropriate 1,2,4,5-tetrahydropyrrolo[3,2,1-jk][l,4]benzodiazepin 7(6H) one (V) with a palladium catalyst in the presence of an inert solvent at a temperature of from 100200 C. for a period of l to 3 hours. Solvents that can be used in this procedure include quinoline, decalin, p-cymene, naphthalene and mesitylene. The product is recovered by conventional procedures such as crystallization, evaporation, chromatography and combinations thereof. This procedure cannot be utilized to prepare compounds of Formula IIIb wherein R is halogen because the procedure removes halogen sub'stituents from the aromatic ring.

In the second dehydrogenation procedure, the 1,2,4,5- tetrahydropyrrolo[3,2, jk][1,4]benzodiazepin 7 (6H)- one is refluxed with either chloroanil or 2,3-dichloro-5,6- dicyano-l,4-benzoquinone in the presence of an inert solvent for 2 to 18 hours. Solvents that can be used in this procedure include benzene, toluene, xylene and the like. The product is recovered by conventional procedures such as crystallization, evaporation, chromatography and combinations thereof.

Compounds of Formula IIIc are prepared in accordance with steps 2 and 3 of process D. In step 2, compounds of [Formula IIIb are reacted with an alkali metal hydride in the presence of an inert solvent at a temperature of 125 C. for 0.5 to 2 hours to prepare the alkali metal salt of IIlb. Solvents that can be utilized include benzene, tetrahydrofuran, dioxane, diglyme, dimethylformamide and dimethyl sulfoxide. In step 3, the reaction mixture containing said alkali metal salt is reacted with an alkyl halide, 4-chloro-4'-fluorobutyrophenone, or tert. aminoalkyl halide having the formula R X wherein X is halogen and R is the same as above to produce IIIc.

(VIII). In step 2, the l-indolinepropionitrile is converted to the corresponding l-indolinepropionic acid (IX). Step 3 involves heating the l-indolinepropionic acid with polyphosphoric acid to form a 1,2,4,5-tetrahydro-6H- The product is recovered by conventional procedures such pyrrolo[3,2,1-ij]quinolin-G-one (X). The conditions as crystallization, evaporation, chromatography and the utilized in these three steps are described in considerable like. detail in :Rapoport et al., J. Org. Chem, 23, 248 (1958).

Process E, which is utilized to prepare 4,5-dihydropyr- In step 4, the l,2,4,5-tetrahydro-6H-pyrrolo[3,2,1-ij]- rolo[1,2,3 ef][1,5]benzodiazepin-6(7H)-ones (Wat) is quinolin-6-one (X) is reacted with sodium azide in the conducted in the same manner and under the same condipresence of polyphosphoric acid to form a mixture of a tions as step 1 of process D. 1,2,4,5 tetrahydropyrrolo[3,2,1-jk] [1,4]benzodiazepin- The 4,5 dihydropyrrolo[3,2,1-jk][l,4]benzodiazepin- 7(6H)-one (V) and a 1,2,4,5-tetrahydropyrrolo[1,2,3-ef] 7(6I-I)-ones (IIIe) and the 4,5-dihydropyrrolo[1,2,3-efl [l,5]benzodiazepin-6(7H)-one (VI). These compounds [1,5]benzodiazepin-6(7H)-one's (IVb) are prepared by are readily separated by conventional procedures such processes F and G, respectively. In process F the starting as crystallization, evaporation, chromatography and material is a compound of Formula IIId, prepared in combinations thereof. The preferred temperature at which process D, and in process G the starting materials is a this reaction is conducted is 50 to 60 C.; however, compound of Formula IVa, prepared in process E. In higher or lower temperatures may be utilized if desired. these processes, the starting compounds are reacted with The molar ratio of ketone to sodium azide should be 1 a mixture of 25% aqueous dialkylamine (having the forto 1.3 and the reaction time is from 1 to 5 hours. mula The acid addition salts of the invention comprise the u! salts of the compounds of Formulae I, II, III and IV as H N noted above, with pharmacologically acceptable acids such as sulfuric, hydrochloric, nitric, phosphoric, lactic,

benzoic, methanesulfonic, p-toluenesulfonic, salicylic, acewherein R is the same as above), 37% aqueous formal- P p maleic, malic, tartaric, Citric, cyclohexamd h d d l i l acetic id at a temperature f 25 sulfamic, succinic, nicotinic, ascorbic acids, and the like. 50 C. f 1 to 1 h Th product i recovered f The novel compounds of this invention exhibit tranh reaction mixture b conventional progedufes h as quil-izi-ng and anticonvulsant activity. This activity was crystallization, evaporation, chromatography and cornbievaluated y 1156 Of the following testsnations thereof.

The 1,2,4,5-tetrahydropyrrolo[3,2,l-jk][1,4]benzodi- Chlmney [Med- 11 (1961)] azepin-7(6H)-ones (V) and the 1,2,4,5-tetrahydropyr- This test determines the ability of mice to back up rolo[1,2,3-ef][1,5]benzodiazepin-6(7H)-ones (VI) emand out of a vertical glass cylinder within 30 seconds ployed as starting materials in the above processes D and Failure of mice to back up and out within this time E can be prepared by the process illustrated by the folindicates tranquilization. lowing equations in which R is the same as above.

Dish test Step 1 Step 2 Mice in Petri dishes (10 cm. diameter, 5 cm. high and R R 1 partially imbedded in wood shavings) climb out in a very 2] J short time, when not treated. Mice remaining in the dish I for more than 3 minutes indicates tranquilization. H CHQCHZCN VII VIII Pedestal test Mouse is placed on a pedestal. The untreated mouse R 7 Step 3 R 7 t p 4 leaves the pedestal in less than a minute to climb back 5 to the floor of the standard mouse box. Tranquilized mice N will stay more than 1 minute.

(BH CHzCOOH U Nicotine antagonism test 0 Thirty minutes after mice in a group are treated with IX X the test compound, both the treated and untreated mice are injected with 2 mg./kg. of nicotine salicylate. The 5 untreated mice show overstimulation, i.e., (1) running R R convulsion followed by (2) tonic extensor fits, followed by (3) death. An eflective nicotine antagonist will pro- N N tect the treated mice against (2) and (3). 0= EN The results of the above tests utilizing some of the N 0 novel compounds of this invention (administered intra- I 0 peritoneally) are set forth in Table I. The results are ex- H pressed in terms of the mg./ kg. dosages at which the tested V VI compounds exhibited activity in 50 of the mice (ED Step 1 involves reacting the appropriate indoline (VII) The structures of the various compounds are set forth with acrylonitrile to form a l-i-ndolinepropionitrile in Table II.

TABLE I Compound 1 2 a 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Chimney 45 10 50 100 36 40 25 100 50 50 36 2o 16 45 e3 Dish 10 12 50 100 45 7.1 50 40 9 89 50 25 35 20 32 a5 20 Pedestal 9 23 50 63 100 14 32 50 23 100 50 50 40 25 32 89 20 'in 15 11 12 1s 45 12.5 as 50 15 20 50 40 45 25 15 200 as D 25 11 12 18 45 12.5 36 50 15 20 50 40 45 25 15 159 53 1 N.A.=Nic0tina antagonism. 3 TE=Tonic extensor fits. 3 D=Death.

TABLE II R R R R i J HN II I .R R! R J R n N HN N 1's 0 RI RI! H H H -(CH2)2N(CZH5)2 H 2)a 3)2 H CH H (J H oH2).-o--F H -CHzN(CH3)5 H CHzN(CH3)2 H H I H H2)2N( 2 s)2 H -(CH2)3N(CH1)2 H OH; H

ECHZN(CI13)3 IIIIIIIIIIIIIIIIIIIIIIIIIIII-CH2N(OH1)2 For purposes of administration to birds and to mam- EXAMPLE 1 mals, including animals of economic value such as horses, cattle, sheep, pigs, mice, rats, rabbits and the like, the ifgfglg novel compounds of the invention can be combined with solid or liquid pharmaceutical carriers and formu- A mlXture 0f 1 of 3. 5 lated in the form of tablets, powder packets, capsules and Y Py [1,5]beI1Z0d1aZeP1I1 0116,

or R" is R!!! Gila-N as defined above also form thiocyanic acid addition salts which when condensed with formaldehyde, form resinous materials useful as pickling inhibitors according to U.S.

Patent 2,425,320 and U.S. Patent 2,606,155. The fluosilicic acid addition salts of said compounds are useful as mothproofing agents according to U.S. Patents 1,915,- 334 and 2,075,359.

The following examples are set forth to illustrate my invention and to enable persons skilled in the art to better understand and practice the invention and are not intended to limit the same.

280 m1. of Decalin and 8.4 g. of 10% palladium-on-carbon catalyst is refluxed under nitrogen for 1.5 hours, cooled and diluted with 1000 ml. of Skellysolve B hexanes. This mixture is kept in an ice bath for 2 hours and then filtered. The solid is washed with Skellysolve B hexanes and extracted with hot methanol. The methanol extract is concentrated, and the residue is crystallized from methanol-ethyl acetate to give 14.1 g. of crude product. This product is recrystallized from ethyl acetate to yield 4,5-dihydropyrrolo[1,2,3-ef] [1,5]benzodiazepin- 6(7H)-one, melting point 2102l4 C.

Analysis.Calcd. for C H N O (percent): C, 70.95; H, 5.41; N, 15.05. Found (percent): C, 71.06; H, 5.41; N, 14.71.

EXAMPLE 2 4,5,6,7-tezrahydropyrr0l0[1,2,3-ef] [1,5] benzodiazepine A solution of 11.1 g. (0.0592 mole) of 4,5-dihydropyrrolo[1,2,3-ef][1,5]benzodiazepin 6(7H) one (Example l) in 900 ml. of tetrahydrofuran is added under nitrogen to a stirred, refluxing suspension of 11 g. of lithium aluminum hydride in 500 ml. of tetrahydrofuran and the resulting mixture is refluxed for 18 hours, cooled in an ice bath and treated successively with 11 ml. of water, 11 ml. of 15% aqueous sodium hydroxide and 33 ml. of Water. This mixture is stirred for about 1 hour and filtered. The filtrate is concentrated in vacuo and the residue is crystallized from ethyl acetate-Skellysolve B hexanes to give 7.87 g. of crude product. This product is recrystallized from ethyl acetate-Skellysolve B hexanes to yield 4,5,6,7-tetrahydropyrrolo[1,2,3-ef] [1,5]benzodiazepine, melting point 79.5-80.5 C.

Amzlysis.Calcd. for C H N (percent): C, 76.71; H, 7.02; N, 16.27. Found (percent): C, 76.82; H, 7.13; N, 16.21.

EXAMPLE 3 9-chZora-4,5-dihydropyrrolo [1,2,3-ef] [1,5] benzdiazepin-6 (7H) -one A stirred mixture of 38.9 g. (0.175 mole) of 9-chloro- 1,2,4,5 tetrahydropyrrolo[l,2,3-ef] [1,5]benzodiazepine- 6(7H)-one, 48 g. (0.211 mole) of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and 780 ml. of benzene is refiuxed under nitrogen for 7 hours and allowed to stand at ambient temperature for 18 hours. The solid is collected by filtration, washed with benzene, and stirred for 1.5 hours with a mixture of dilute aqueous sodium hydroxide (1.5 l.) and methylene chloride (1.5 1.). The resulting solid is collected by filtration and washed with dilute aqueous sodium hydroxide. The aqueous filtrate is extracted with methylene chloride, and the solid is extracted several times with boiling methylene chloride. The combined methylene chloride extracts are washed with a saturated solution of sodium chloride, dried over anhydrous potassium carbonate and concentrated in vacuo. The residue is crystallized from methylene chloride-methanol (decolorizing charcoal treatment) to give 20.5 g. of crude product. The product is recrystallized from methylene chloride-methanol to give 9-chloro-4,S-dihydropyrrolo- [1,2,3-ef] [1,5]benzodiazepin-6(7H)-one, melting point 234-235 C.

Analysis.Calcd. for C H ClN O (percent): C, 59.87; H, 4.11; Cl, 16.07; N, 12.70. Found (percent): C, 59.85; H, 4.26;Cl, 16.24; N, 12.86.

EXAMPLE 4 9-chl0r0-4,5,6,7-tetrahydropyrrolo [1,2,3-ef] [1,5]-

benzodiazepine A solution of 8.0 g. (0.0364 mole) of 9-chloro-4,5- dihydropyrrolo[1,2,3-ef][1,5]benzodiazepin-6(7H) one (Example 3) in 600 ml. of tetrahydrofuran is added under nitrogen to a stirred, refluxing suspension of 8.0 g. of lithium aluminum hydride in 400 ml. of tetrahydrofuran, and the resulting mixture is refluxed for 8 hours and allowed to stand at ambient temperature for 18 hours. This mixture is cooled in an ice bath and treated successively with 8 ml. of water, 8 ml. of 15% aqueous sodium hydroxide and 24 ml. of water. The resulting mixture is stirred for 1 hour and filtered. The filtrate is concentrated in vacuo, and the residue is crystallizeed from ethyl acetateSkellysolve B hexanes to give 6.3 g. of crude product. The product is recrystallized from ethyl acetateSkellysolve B hexanes to give 9-ch1oro-4,5,6,7-tetrahydropyrrolo[1,2,3-ef][1,5]benzodiazepine, melting point 128.5- 129.5 C.

Analysis.-Calcd. for C H ClN (percent): C, 63.92; H, 5.37; Cl, 17.16; N, 13.56. Found (percent): C, 64.20; H, 5.37; Cl, 17.17; N, 13.55.

EXAMPLE 1-(dimethylaminomethyl) -4,5-dz'hydropyrr0l0[1,2,3-ef1- [1 ,5 1 benz0diazepin-6 (7H -one A solution of 25% aqueous dimethylamine (2.43 ml.) is cooled with stirring in an ice bath and treated successively with 5.0 ml. of acetic acid and 0.893 ml. of 37% aqueous formaldehyde. This solution is allowed to warm to ambient temperature and is treated with 1.86 g. (0.010 mole) of 4,5-dihydropyrrolo[1,2,3-ef] 1,5 ]benzodiazepin- 6(7H)-one (Example 1). This mixture is stirred, under nitrogen, for 3 hours and poured into ice water. The cold solution is made alkaline with sodium hydroxide and the precipitate is collected by filtration, washed with water and dried to give 2.17 g. of crude product. Recrystallization of this product twice from methanol-ethyl acetate yields 1-(dimethylaminomethyl)-4,5-dihydropyrrolo[1,2, 3-ef][1,5]benzodiazepin-6(7H)-one, melting point 193 193.5 C.

Analysis.-Calcd. for C H N O (percent): C, 69.11; H, 7.04; N, 17.27. Found (percent): C, 68.90; H, 6.92; N, 17.06.

EXAMPLE 6 4,5 -dihydropyrrolo [3,2,1 -jk] [1,4] benzodiazepin- 7 (6H -one A stirred mixture of 23.8 g. (0.127 mole) of 1,2,4,5- tetrahydropyrrolo[3,2,1 jk] [1,4]benzodiazepin 7 (6H)- one, 380 ml. of decalin and 11.5 g. of 10% palladium-oncarbon catalyst is refluxed under nitrogen for 1.5 hours. The mixture is cooled in an ice bath, diluted with 450 ml. of Skellysolve B hexanes and allowed to crystallize. The solid is collected by filtration, washed with Skellysolve B hexanes and extracted with methanol. The methanol extract is concentrated under reduced pressure, and the residue is crystallized from methanol-ethyl acetate to give 16.19 g. of crude product. This crude product is recrystallized from methanol-ethyl acetate to yield 4,5dihydropyrrolo[3,2,1-jk] [1,4]benz0diazepin-7(6H) one, melting point l73-174 C.

Analysis.-Calcd. for C H N O (percent): C, 70.95; H5, 5.41; N, 15.05. Found (percent): C, 71.34; H, 5.41; N, 1 .01.

EXAMPLE 7 4,5,6,7-tetrahydropyrrola[3,2,1-jk] [1,41benz0diazepine A solution of 11.2 g. (0.0604 mole) of 4,5-dihydropyrrolo[3,2,1-jk] [1,4]benzodiazepin-7(6H)-one (Example 6) in 900 ml. of dry tetrahydrofuran is added under nitrogen to a stirred, refluxing suspension of 11.5 g. of lithium aluminum hydride in 500 ml. of tetrahydrofuran. The resulting mixture is refluxed for 18 hours, cooled in an ice bath and treated successively with 11.5 ml. of water, 11.5 ml. of 15 aqueous sodium hydroxide and 34.5 ml. of water. The solid is collected by filtration and the filtrate is concentrated under reduced pressure. Crystallization of the residue from ethyl aceetate-Skellysolve B hexanes gives 5.32 g. of crude product. Recrystallization of this crude product from ethyl acetate-Skellysolve B hexanes yields 4,5,6,7 tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepine, melting point 62.563.5 C.

tAnalysis.Calcd. for C H N (percent): C, 76.71; H, N, 16.27. Found (percent): C, 76.83; H, 7.05; N,

EXAMPLE 8 9-chl0r0-4,5-dihydr0pyrrolo[3,2,1-jk] [1,4] benzodz'azepin- 7 (6H) -one A stirred mixture of 10.0 g. (0.0450 mole) of 9-chloro- 1,2,4,5 tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin- 7(6H)-one, 12.3 g. (0.0542 mole) of 2,3-dichloro-S,6-dicyano-1,4-benzoquinone and 200 ml. of dry benzene is refluxed under nitrogen for 7 hours, cooled and filtered. The resulting solid is suspended in a mixture of about 400 ml. of cold dilute aqueous sodium hydroxide and about 400 ml. of methylene chloride, stirred for 30 minutes and the mixture is filtered. The methylene chloride solution is washed with a saturated solution of sodium chloride, dried over anhydrous potassium carbonate and concentrated. Crystallization of the residue from tetrahydrofuran (decolorizing charcoal treatment) gives 2.20 g. of crude product. The sticky solid obtained from the above filtration is mixed with diatomaceous earth, washed several times with cold, dilute aqueous sodium hydroxide and then with water, and then extracted with a hot methanolmethylene chloride solution. The extract is concentrated and the residue is crystallized from tetrahydrofuran to give an additional 3.81 g. of crude product. The two crops of product are combined and recrystallized from methanol-methylene chloride to yield 9-chloro-4,5-dihydropyrrolo[3,2,1-jk] [1,4]benzodiazepin 7(6H) one, melting point 231.5-232.5 C.

AnaZysis.-Calcd. for C H ClN O (percent): C, 59.87; H, 4.11; Cl, 16.07; N, 12.70. Found (percent): C, 59.68; H, 3.93; CI, 16.19; N, 12.27.

EXAMPLE 9 9-chl0r0-4,5 ,6, 7-tetrahy dropyrrolo[3,2,1 jk] [1 ,4] benzodiazepine A solution of 3.80 g. (0.0172 mole) of 9-chloro-4,5- dihydropyrrolo[3,2,1][1,4]benzodiazepin 7(6H) one (Example 8) in 430 ml. of tetrahydrofuran is added under nitrogen to a stirred refluxing suspension of 3.8 g. of lithium aluminum hydride in 170 ml. of tetrahydrofuran and the resulting mixture is refluxed for 8 hours and allowed to stand at ambient temperature 18 hours. The mixture is then cooled in an ice bath and treated successively with 3.8 m1. of Water, 3.8 ml. of 10% aqueous sodium hydroxide and 11.4 ml. of water. The mixture is stirred for about 1 hour and filtered. The filtrate is con centrated under reduced pressure, and the residue is crystallized from ether-Skellysolve B hexanes to give 2.91 g. of crude product. This product is recrystallized from ether-Skellysolve B hexanes to give 9-chloro-4,5,6,7-tetrahydropyrrolo[3,2,1] [1,4]benzodiazepine, melting point 70-71.5 C.

Analysis.-Calcd. for C H ClN (percent): C, 63.92; H, 5.37; Cl, 17.16; N, 13.56. Found (percent): C, 63.83; H, 5.36; Cl, 17.17; N, 13.38.

EXAMPLE 10 6 [2 (diethylamino)ethyl] 4,5 dihydropyrrol[3,2, I jk] [1,4] benzodiazepin 7 (6H) one and oxalate thereof A stirred solution of 12.0 g. (0. 0645 mole) of 4,5-dihydropyrrolo[3,2,1] [1,41benzodiazepin 7 (6H) one (Example 6) in 650 ml. of dry dimethyl formamide under nitrogen is treated with a 57.1% mineral oil suspension of sodium hydride (2.98 g.) and warmed on the steam bath for 45 minutes. This mixture is cooled in an ice bath, treated with a solution of 10.5 g. of 2 (diethylamino)ethyl chloride in 90 ml. of ether, kept at ambient temperature for 18 hours and concentrated in vacuo. A suspension of the residue in water is extracted with methylene chloride. The extract is dried over anhydrous potassium carbonate and concentrated under reduced pressure. Chromatography of the residue on 1.2 kg. of silica gel with benzene-2% triethylamine-88% methanol (by volume) gives 6 [2 (diethylamino)ethyl] 4,5 dihydropyrrolo[3,2,1 jk][1,4]benzodiazepin 7(6H) one. This base is converted to its oxalate salt by treating an ethanol solution of it with one molar equivalent of oxalic acid. The product thus obtained is recrystallized twice from ethanol-ethyl acetate to yield 6 [2- diethylamino)ethyl] 4,5 dihydropyrrolo[3,2,1 jk][1,4] 'bgnzodiazepin 7(6H) one oxalate, melting point 168- 1 0 C.

Analysis.Calcd. for C H N O-C H O (percent): C, 60.78; H, 6.71; N, 11.19. Found (percent): C, 60.83; H, 6.67; N, 11.22.

EXAMPLE 11 6 [2 (diethylamino)ethyl] 4,5,6,7 tetrahydropyrr0lo[3,2,1 jk][1,4]benz0diazepine and dihydrochloride thereof A solution of 11.0 g. (0.0386 mole) of 6 [2 (diethyl amino)ethyl] 4.5 dihydropyrrolo[3,2,1][1,4]benzodiazepin 7(6H) one (Example 10) in 350 ml. of tetrahydrofuran is added, under nitrogen, to a stirred refluxing suspension of 11 g. of lithium aluminum hydride in 250 ml. of tetrahydrofuran. The resulting mixture is refluxed for 18 hours, cooled in an ice bath and treated successively with 11 ml. of Water, 11 ml. of aqueous sodium hydroxide and 33 ml. of Water. This mixture is stirred for about 1 hour and filtered. The filtrate is concentrated in vacuo, the residue is dissolved in 95% ethanol, and the solution is acidified with methanolic hydrogen chloride. The resulting salt is crystallized from ethanol-ethyl acetate to give 8.41 g. of crude product. The product is recrystallized from ethanolethyl acetate to give 6 [2 (diethylamino)ethyl] 4,5,6,7 tetrahydropyrrolo[3,2,1 jk] [1,4]benzodiazepine dihydrochloride, melting pont 244.5246.5 C.

Analysis.-Calcd. for C H N -2HCl (percent): C, 59.30; H, 7.91; CI, 20.59; N, 12.20. Found (percent): C, 59.47; H, 7.83; Cl, 20.69 N, 11.93.

The free base, 6 [2 (diethylamino)ethyl] 4,5,6,7- tetrahydropyrrolo[3,2,1 jk][1,4]'benzodiazepine, is prepared by basifying an aqueous solution of the above dihydrochloride with sodium hydroxide, extracting the mixture with ether and evaporating the extract to dryness.

EXAMPLE 12 6-[3-(dimelizylamino')propyl] -4,5-dihydr opyrr0l0- [3,2,1-jk] [1,4] benzodiazepin-7(6H) -one A stirred solution of 12.0 g. (0.0646 mole) of 4,5-dihydropyrrolo[3,2,1-jk][1,4]benzodiazepin 7(6H) one (Example 6) in 700 ml. of dry dimethylformarnide is treated With a 57.1% suspension of sodium hydride in mineral oil (2.99 g.). The resulting mixture is warmed, under nitrogen, on a steam bath for 1 hour, cooled in an ice bath and treated with a solution containing 8.65 g. of 3-(dimethylamino)propyl chloride and m1. of ether. This mixture is kept at ambient temperature for 18 hours and concentrated in vacuo. The residue is suspended in water and extracted with methylene chloride. The extract is dried over anhydrous potassium carbonate and concentrated. The residue is chromatographed on 1 kg. of silica gel with 2% triethylamine-48% methanol- 50% ethyl acetate (by volume) and the desired material thus obtained is crystallized from ethyl acetate-Skellysolve B hexanes to give 10.62 g. of crude product. This product is recrystallized from ethyl acetate to give 6-[3 (dimethylamino)propyl] 4,5 dihydropyrrolo[3,2,1-jk] [1,4]benzodiazepin 7(6H) one, melting point 101.5 102.5 C.

Analysis.Calcd. for C H N O (percent): C, 70.82; H, 7.80; N, 15.49. Found (percent): C, 70.57; H, 7.76; N, 15.91.

EXAMPLE 13 6 [3 (dimethylamino)propyl] 4,5,6,7 tetrahydropyrr0l0[3,2,l jk] [1,4]benzodiazepine and dihydrochloride thereof A solution of 8.05 g. (0.0295 mole) of 6 [3 (dimethylamino)propyl] 4,5 dihydropyrrolo[3,2,1 jk][1,4] 'benzodiazepin-7(6H)-one (Example 12) in 250 ml. of tetrahydrofuran is added under nitrogen to a refluxing suspension of 8.0 g. of lithium aluminum hydride in 200 ml. of tetrahydrofuran, and the resulting mixture is refluxed for 18 hours, cooled in an ice bath and treated successively with 8 ml. of Water, 8 m1. of 15 aqueous sodium hydroxide and 24 ml. of Water. The mixture is stirred for about 1 hour and filtered. The filtrate is concentrated in vacuo to yield 6 [3 (dimethylamino)propyl] 4,5,6,7 tetrahydropyrrolo[3,2,1 jk][1,4]-benzodiazepine.

A solution of this base in methanol is acidified with methanolic hydrogen chloride and the resulting salt is recrystallized twice from methanol-ethyl acetate to give hydrated 6 [3 (dimethylamino)propyl] 4,5,6,7 tetrahydropyrrolo[3,2,1 jk] [1,4] benzodiazepine dihydrochloride, melting point 244-246 C.

Analysis.--Calcd. for C H N -2HCl (percent): C, 58.18; H, 7.63; Cl, 21.47; N, 12.72. Found (percent): C, 55.70; H, 7.70; CI, 20.79; N, 12.46; E 0, 3.81. Found after correction for 3.81% H O (percent): C, 57.91; H, 7.56; Cl, 21.61; N, 12.95.

The hydrated 6-[3-(dimethylamino)propyl] 4,5,6,7- tetrahydropyrrolo 3 ,2, 1 -jk] [1,41beuzodiazepine dihydro- 13 chloride is maintained at about 110 C. and about 12 mm. of mercury pressure for 48 hours, to obtain anhydrous 6 [3(dimethylamino)propyl]-4,5,6,7-tetrahydropyrrolo[3,2,1-jk] [1,4]benzodiazepine dihydrochloride.

EXAMPLE 14 4,5-dihydr-6-methylpyrrolo [3,2,1-jk] [1,4]

benzodiazepin-7(6H) -0ne A stirred solution of 10.0 g. (0.0538 mole) of 4,5-dihydropyrrolo[3,2,1-tjk][1,4]benzodiazepin 7(6H) one (Example 6) in 500 ml. of dry dimethylformamide is cooled in an ice bath under nitrogen and treated with a 57.1% mineral oil suspension of sodium hydride (2.43 g). The resulting mixture is warmed on the steam bath for 1 hour, cooled in an ice bath and treated with a solution of 8.38 g. of methyl iodide in 90 ml. of ether. This mixture is kept at ambient temperature for 18 hours and concentrated in vacuo. The residue is suspended in water and extracted with methylene chloride. The extract is dried over anhydrous potassium carbonate and concentrated in vacuo. The residue is chromatographed on 800 g. of silica gel with 50% acetone-50% Skellysolve B hexanes (by volume). The desired crude product is the first material eluted from the column. This product is recrystallized twice from ethyl acetate-Skellysolve B hexanes to yield 4,5 dihydro 6-methylpyrrolo[3,2,1-jk] [1,4]benzodiazepin-7(6H)-one, melting point 1055-1065 C.

Analysis.-Calcd. for C I-L N O (percent): C, 71.98; H, 6.04; N, 13.99. Found (percent): C, 71.98; H, 5.70; N, 13.96.

EXAMPLE 15 4,5,6,7-tetrahydro-6-methylpyrrolo[3,2,1-jk] [1,4] benzodiazepine A solution of 5.32 g. (0.0266 mole) of 4,5-dihydro-6- methylpyrrolo[3,2,1-jk] [1,4]benzodiazepin 7 (6H) one (Example 14) in 150 ml. of tetrahydrofuran is added, under nitrogen, to a stirred, refluxing suspension of .3 g. of lithium aluminum hydride in 200 ml. of tetrahydrofuran. The resulting mixture is refluxed for 18 hours, cooled in an ice bath and treated successively with 5.3 ml. of water, 5.3 ml. of 15% aqueous sodium hydroxide and 15.9 ml. of water. This mixture is stirred for about 1 hour and filtered. The filtrate is concentrated in vacuo. Recrystallization of the residue twice from petroleum ether, at 0 0., gives 4,5,6,7-tetrahydro-o-methylpyrrolo [3,2,1-jk] [1,4]-benzodiazepine, melting point 425-44 0.

Analysis.Calcd. for C H N (percent): C, 77.38; H, 7.58; N, 15.04. Found (percent): C, 77.06; H, 7.44; N, 14.82.

EXAMPLE 16 4'-flu0r0-4- (4,5-dihydropyrrol0[3,2,1-jk] [1,4] benz0diazepin-6 (7H) -yl butyrophenone A mixture of 1.72 g. (0.010 mole) of 4,5,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepine (Example 7), 2.82 g. of 4-chloro-4'-fluorobutyrophenone, 3.22 g. of anhydrous sodium carbonate, 70 mg. of potassium iodide and 130 ml. of 4-methyl-2-pentanone is refluxed under nitrogen for 14 hours, cooled and poured into ice water. The layers are separated and the aqueous layer is extracted with ether. The combined organic layer is dried over anhydrous potassium carbonate and concentrated in vacuo. The residue is chromatographed on 200 g. of silica gel with 70% ethyl acetate-30% cyclohexane (by volume) and 100 ml. fractions are collected. The crude product is eluted in fractions 14-23 and recrystallized twice from ethyl acetate-Skellysolve B hexanes to give 4'-fluoro-4-(4,5-dihydropyrrolo[3,2,1 jk] [1,4] 'benzodiazepin-6 (7H)-yl)butyrophenone, melting point 90-91 C.

Analysis.Calcd. for C H FN O (percent): C, 74.97; H, 6.29; F, 5.65; N, 8.33. Found (percent): C, 74.80; H, 6.27; F, 5.59; N, 8.50.

14 EXAMPLE 17 I-(dimethylaminomethyl)-4,5-dihydropyrr0l0- [3,2,1 -jk] [1 ,4 benzodiazepin-7(6H )-one A solution (2.43 ml.) of 25% aqueous dimethylamine is cooled with stirring in an ice bath and treated successively with 5 ml. of acetic acid and 0.893 ml. of 37% aqueous formaldehyde. This solution is allowed to warm to ambient temperature and is treated with 1.86 g. (0.010 mole) of 4,5-dihydropyrrol0[3,2,l-jk] [l,4]benzodiazepine-7(6H)-one (Example 6). This mixture is stirred, under nitrogen, for 2 hours and poured into ice water. The resulting solution is made alkaline with dilute aqueous sodium hydroxide and extracted with methylene chloride. The extract is dried over anhydrous potassium carbonate and concentrated in vacuo. The residue is treated with ethyl acetate and a small amount of insoluble material is removed by filtration. The filtrate is concentrated and crystallized to yield 1.43 g. of crude product. This product is recrystallized from ethyl acetate to give l-(dimethylaminomethyl)-4,5-dihydropyrrolo[3,2,1- jk] [1,4]benzodiazepin-7(6H)-one, melting point 171- 172.5 C.

Analysis.-Calcd. for C H N O (percent): C, 69.11; H, 7.04; N, 17.27. Found (percent): C, 69.22; H, 7.24; 'N, 17.30.

EXAMPLE 18 1 (dimethylaminomethyl) 4,5,6,7-tetrahydropyrrolo- [3,2,1 jk] [1,4] benzodiazepine and dihydrobromide thereof l-(dimethylaminomethyl) 4,5 d-ihydropyrrolo[3,2,1- jk] [1,4]benzodiazepin-7(6H)-one (9. 64 g., 0.0392 mole) (Example 17) is added, under nitrogen, to an ice cold stirred suspension of 9.6 g. of lithium aluminum hydride in 1.2 l. of tetrahydrofuran, and the resulting mixture is refluxed for 7 hours and kept at ambient temperature for 18 hours. It is then cooled in an ice bath and treated successively with 9.6 ml. of water, 9.6 ml. of 15% aqueous sodium hydroxide and 28.8 ml. of water. The solid is collected by filtration, and the filtrate is concentrated in vacuo. The residue is crystallized at 6 C. from ethyl acetate-Skellysolve B hexanes to give 7.38 g. of crude product. Recrystallization of this product from ethyl acetate-Skellysolve B hexanes yields l-(dimethylaminomethyl) 4,5,6,7 tetrahydropyrrolo[3,2,1-jk] [1,41benzodiazepine, melting point 67.5-68.5 C.

Analysis.-Calcd. for C H -N (percent): C, 73.32; H. 8.35; N, 18.33. 'FOlltild (percent): C, 73.40; H, 8.32; N. 18.22.

A solution of l-(dimethylaminomethyl)4,5,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepine in ethyl acetate is acidified with methanolic hydrogen bromide, and the resulting product is recrystallized from methanolethyl acetate to yield 1-(dimethylaminomethyl)-4,5,6,7- tetrahydropyrrolo[3,2,1-jk] [1,4] benzodiazepine dihydrobromide, melting point 227 C. (dec.).

Analysis.-Calcd. for C H N -2HBr (percent): C, 42.98; H, 5.41; Br, 40.86; N, 10.74. Found (percent): C, 42.89; H, 5.28; Br, 40.70; N, 10.58.

EXAMPLE 19 9-chlor0-1- (dimethylaminomethyl -4,5-dihy dropyrrolo- [3,2,1-jk] [1,4] benz0diazepin-7(6H) -one Aqueous dimethylamine (25%) (2.43 ml.) is cooled in an ice bath and treated successively with glacial acetic acid (5 ml.) and 27% aqueous formaldehyde (0.89 ml.). This solution is warmed to 18 C. and treated with 2.20 g. (0.010 mole) of 9-chloro-4,5-dihydropyrrolo[3,2,1-jk] [1, 4]benzodiazepin-7(6H)-one (Example 8). This mixture is stirred at ambient temperature for 2 hours, at 40-50 C. for 1.25 hours and at C. for 45 minutes. It is then poured into ice water and made alkaline with 15 aqueous sodium hydroxide. The initially formed gum crystal- 15 lizes and is collected by filtration and dried to give 2.36 g. of 9-chloro-l-(dimethylaminomethyl)-4,5-dihydropyrrolo [3,2,1 jk] [1,4]benzodiazepin-7(6H)-one, melting point 228231 C. (dec.).

EXAMPLE 20 9 chIoro-J-(dimethylaminmethyl)-4,5,6,7-telralzydr0pyrr0l0[3,2,1-jk] [1,4]benz0diazepine and dihydrochloride thereof To a stirred suspension of 2 g. of lithium aluminum hydride in 500 m1. of tetrahydrofuran is added 2.08 g. of 9 chloro 1-(dimethylaminomethyl)-4,5-dihydropyrrolo [3,2,1-jk] [1,4]benzodiazepin-7(6H)-one (Example 19), and the resulting mixture is refluxed under nitrogen for 18 hours, cooled and treated successively with 2 ml. of water, 2 ml. of 15% aqueous sodium hydroxide and 6 ml. of water. This mixture is stirred for 1 hour and filtered. The filtrate is concentrated in vacuo to yield 9-chloro-1- dimethylaminomethyl) 4,5, 6,7-tetrahydropyrrolo [3,2,1- jk] [1,4]-benzodiazepine as a residue.

9 chloro 1(dimethylaminomethyl)-4,5,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepine is dissolved in 95% ethanol and acidified with methanolic hydrogen chloride. The mixture is filtered and the recovered solid is recrystallized from methanol-ethyl acetate to give 9- chloro 1 (dimethylaminomethyl)-4,5,6,'7tetrahydr0 pyrrolo[3,2,1 jk][1,4]benzodiazepine dihydrochloride, melting point 243-244.5 C.

Analysis.--Calcd. for C H ClN -2HCI (percent): C, 49.94; H, 5.99; Cl, 31.59; N, 12.48. Found (percent): C, 49.91; H, 6.27; CI, 30.69; N, 12.14.

I claim:

1. A compound selected from the group consisting of (a) a compound having the formula wherein R is selected from the group consisting of hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive, alkoxy of from 1 to 3 carbon atoms, inclusive, and 'halogen; wherein R is selected from the group consisting of hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive, 4oxo-4-(p-fiuorophenyl)butyl, the group z)nN wherein n is an integer of from 2 to 4, inclusive, and R 1s alkyl of from 1 to 3 carbon atoms, inclusive; and wherein R" is hydrogen or the group R! CH2=N/ RI/I wherein R' is the same as above; and (b) the addition salts with pharmacologically acceptable acids of the compound of the above formulae.

2. A compound of claim 1 having the formula of I.

3. A compound of claim 2 wherein R, R' and R" are each hydrogen.

4. A compound of claim 2 wherein R is 9-chloro and R and R" are each hydrogen.

5. A compound of claim 2 wherein R and R" are each hydrogen and R is 2-(diethylamino)ethyl.

6. The dihydrochloride of the compound of claim 5.

7. A compound of claim 2 wherein R and R are both hydrogen and R is 3-(dimethylamino)propyl.

8. The dihydrochloride of the compound of claim 7.

9. A compound of claim 2 wherein R and R" are both hydrogen and R is methyl.

10. A compound of claim 2 wherein R and R are both hydrogen and R is 4-oxo-4-(p-fluorophenyl)butyl.

11. A compound of claim 2 wherein R and R are both hydrogen and R is dimethylaminomethyl.

12. A compound of claim 2 wherein R is 9-chl0ro, R is hydrogen and R is dimethylaminomethyl.

13. The dihydrochloride of the compound of claim 12.

14. A compound of claim 1 having the formula of 11.

15. A compound of claim 14 wherein R and R are each hydrogen.

16. A compound of claim 14 wherein R is 9-chloro and R is hydrogen.

References Cited UNITED STATES PATENTS 9/1969 SulkoWski et al. 260326.1 9/1969 Sulkowski et al. 260-326.1

OTHER REFERENCES Theilheimer, Synthetic Methods of Organic Chemistry (1958) vol. 12:513.

ALEX MAZEL, Primary Examiner I. A. NARCAVAGE, Assistant Examiner #2565 UNITED STATES PATENT UFFICE CERTEFICATE or to ECEWN Patent No. 3b42 3821 Dated Novembe r 5: 9 9

Inventor(s) J B Heste r J F It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 2, l ine 50, should appear as shown below instead of as in the patent:

Column l, l ine +1, for "-8 (6H) read -7 (6H) Column 4, l ine l}, for (6H -ones read (oH)-ones Column l, l ine +6, for "procedu res read procedure Column 4, l ine 60-, for "[12, -j k] read [5,2,1-j k] Column 7, l ines 15-20, should appear as shown below instead of as in the patent FORM PO-lOSO (10-69) USCOMM-DC 60376-P69 w u.s GOVERNMENT PRINTING OFFICE: [969 0-355-334 UNITED STATES PATENT @FFIQE Page 2 QERTIFIEATE OF CO REQ'HN Patent No. 5, November 3, 1969 It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 8, 1 ine 15, for "R" read R Column 8, 1 ine 20, for read IV Column 9, l ine 51, for "crystal 1 izeed" read crystal 1 iz'ed Col umn 10, 1 ine 41, for 'aceetateread acetate- Coiumn l1, 1 ine 9, for "[3,2,1] read [3,2,1-j k] Column 11, I ine 23, for "[5,2,1] read [3,2,1-j k] Column 11, 1 ine 35, for "[3,2,1 1 read [5,2,1-j k] Column 11, 1 ine 66, for "-4.5"

read -4,5-

Column 11, 1 ine 66, for "[3, n read ""y,

C01 umn 14, l ines 10-11, for benz odiaz epi ne- RI! read benzodiazepin- Column 16, I ine 10, for "-CH =N RI?! RIII read -CH -N \RIYI Signed and sealed this 3rd day of April 1973.

(SEAL) Attest:

EDWARD M. FLETCHER,JR.

ROBERT GOTTSCHALK Attestlng Officer Commissioner of Patents FORM PO-lOSO (10-69) USCOMM-DC 60375-P69 U45 GOVERNMENT PRINTING OFFICE: I969 O-365'334 

